Loading...
Loading...
Theravance,
Inc.
THRX today announced that the US FDA has posted on its website briefing documents for
the November 29, 2012 Anti-Infective Drugs Advisory Committee (AIDAC)
meeting. The AIDAC will be asked to review and discuss Theravance's
New Drug Application (NDA) for VIBATIV(R) (telavancin), a
bactericidal, once-daily injectable antibiotic, for the proposed
indication of nosocomial pneumonia (pneumonia contracted by
hospitalized patients), including ventilator-associated pneumonia,
caused by susceptible isolates of the following Gram-positive
bacteria: Staphylococcus aureus (including methicillin-susceptible
and -resistant isolates) or Streptococcus pneumonia (penicillin
susceptible strains).
The Theravance Briefing Document and the FDA Briefing Document are now available at
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-
InfectiveDrugsAdvisoryCommittee/ucm329476.htm.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in